Poster Downloads_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen, drug development, antibody discovery

top

Please input keywords

EN

Management team

Social Responsibility

Antibody Assets

Project Integrum

Antibody discovery platforms

Clinical pipeline

Preclinical pipeline

Humanized animal models

KO mouse models

Immunodeficient mice/rats

Disease mouse models

Pharmacology Service

Therapeutic area

Types of services

By technologies

Animal Breeding

Animal Cryopreservation

Animal Rederivation

Microbial detection

Animal Breeding

Animal Cryopreservation

Animal Rederivation

Stock Information

Financial Reports

Listing Documents

Announcements & Notices

Corporate Governance

Investor Calendar

Poster Downloads

Media Center

Poster Downloads

Brochure

AACR 2023: In vivo Efficacy of an Anti-Human IL11RA Antibody in B-hIL11RA Mice With APAP-Induced Liver Damage

AACR 2023: Novel Humanized CD36 Mouse Model for Therapeutic Studies

AACR 2023: Development of Immunodeficient Mice Expressing Human IL3, GM-CSF, CSF1 and THPO for Improved Human Myeloid and Lymphoid Cell Reconstitution

AACR 2023: Development of MHC I/II Knock-Out Immunodeficient Mouse Strains for Alleviating GvHD Induced by Human PBMC Reconstitution

PEGS-EU 2022:YH013, A Fully-human EGFR x MET Bispecific ADC Exhibits Outstanding Specificity and Anti-tumor Efficacy

PEGS-EU 2022:1C3—A Differentiated Non-Blocking Agonist TNFR2 Antibody for Cancer Immunotherapy

PEGS-EU 2022:A Novel TCR-mimic Fully Human Antibodies Discovery Platform

World ADC San Diego2022丨YH013, a fully-human EGFR x MET bispecific ADC exhibits outstanding specificity and anti-tumor efficacy

ASCO 2022: A phase I open-label dose escalation of YH003 (CD40 mAb) in combination with toripalimab (PD-1 mAb) in patients with advanced solid tumors

1 … 6 7 8 9 10 … 15